Dermatologic Toxicities of Anticancer Therapy

Natalie H. Matthews; Farah Moustafa; Nadine M. Kaskas; Leslie Robinson-Bostom; Lisa Pappas-Taffer

doi:10.1016/B978-0-323-47674-4.00041-4

Dermatologic Toxicities of Anticancer Therapy

Natalie H. Matthews, Farah Moustafa, Nadine M. Kaskas, Leslie Robinson-Bostom, Lisa Pappas-Taffer

Research output: Chapter in Book/Report/Conference proceeding › Chapter › peer-review

1 Scopus citations

Abstract

As with other pharmacologic agents used in the treatment of human disease, the administration of anticancer drugs often results in toxic adverse effects to the skin, hair, and nails. Toxic drug reactions in the skin may occur as idiosyncratic or allergic drug reactions at ordinary therapeutic drug dosages or in a dose-dependent manner. In general, three classes of anticancer agents have unique dermatologic toxicities: cytotoxic chemotherapy, radiation therapy, and targeted anticancer therapy.

Original language	English
Title of host publication	Abeloff’s Clinical Oncology
Publisher	Elsevier
Pages	621-648.e5
ISBN (Electronic)	9780323476744
DOIs	https://doi.org/10.1016/B978-0-323-47674-4.00041-4
State	Published - 1 Jan 2019
Externally published	Yes

Keywords

Cancer treatment
Chemotherapy
Cutaneous adverse events
Dermatologic toxicities
Drug reaction

Access to Document

10.1016/B978-0-323-47674-4.00041-4

Cite this

@inbook{f733d4722fa446a08ca1e8dc34c91790,

title = "Dermatologic Toxicities of Anticancer Therapy",

abstract = "As with other pharmacologic agents used in the treatment of human disease, the administration of anticancer drugs often results in toxic adverse effects to the skin, hair, and nails. Toxic drug reactions in the skin may occur as idiosyncratic or allergic drug reactions at ordinary therapeutic drug dosages or in a dose-dependent manner. In general, three classes of anticancer agents have unique dermatologic toxicities: cytotoxic chemotherapy, radiation therapy, and targeted anticancer therapy.",

keywords = "Cancer treatment, Chemotherapy, Cutaneous adverse events, Dermatologic toxicities, Drug reaction",

author = "Matthews, {Natalie H.} and Farah Moustafa and Kaskas, {Nadine M.} and Leslie Robinson-Bostom and Lisa Pappas-Taffer",

note = "Publisher Copyright: {\textcopyright} 2020 Elsevier Inc.",

year = "2019",

month = jan,

day = "1",

doi = "10.1016/B978-0-323-47674-4.00041-4",

language = "English",

pages = "621--648.e5",

booktitle = "Abeloff{\textquoteright}s Clinical Oncology",

publisher = "Elsevier",

address = "Netherlands",

}

TY - CHAP

T1 - Dermatologic Toxicities of Anticancer Therapy

AU - Matthews, Natalie H.

AU - Moustafa, Farah

AU - Kaskas, Nadine M.

AU - Robinson-Bostom, Leslie

AU - Pappas-Taffer, Lisa

PY - 2019/1/1

Y1 - 2019/1/1

N2 - As with other pharmacologic agents used in the treatment of human disease, the administration of anticancer drugs often results in toxic adverse effects to the skin, hair, and nails. Toxic drug reactions in the skin may occur as idiosyncratic or allergic drug reactions at ordinary therapeutic drug dosages or in a dose-dependent manner. In general, three classes of anticancer agents have unique dermatologic toxicities: cytotoxic chemotherapy, radiation therapy, and targeted anticancer therapy.

AB - As with other pharmacologic agents used in the treatment of human disease, the administration of anticancer drugs often results in toxic adverse effects to the skin, hair, and nails. Toxic drug reactions in the skin may occur as idiosyncratic or allergic drug reactions at ordinary therapeutic drug dosages or in a dose-dependent manner. In general, three classes of anticancer agents have unique dermatologic toxicities: cytotoxic chemotherapy, radiation therapy, and targeted anticancer therapy.

KW - Cancer treatment

KW - Chemotherapy

KW - Cutaneous adverse events

KW - Dermatologic toxicities

KW - Drug reaction

UR - http://www.scopus.com/inward/record.url?scp=85105572327&partnerID=8YFLogxK

U2 - 10.1016/B978-0-323-47674-4.00041-4

DO - 10.1016/B978-0-323-47674-4.00041-4

M3 - Chapter

AN - SCOPUS:85105572327

SP - 621-648.e5

BT - Abeloff’s Clinical Oncology

PB - Elsevier

ER -

Dermatologic Toxicities of Anticancer Therapy

Abstract

Keywords

Access to Document

Fingerprint

Cite this